Antifungal drugs: predicting clinical efficacy with pharmacodynamics

References

• Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis.29, 239–244 (1999).
   PubMed Web of Science ®Google Scholar
• Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect. Dis.3, 685–702 (2003).
   PubMed Web of Science ®Google Scholar
• Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP; National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin. Infect. Dis.35, 627–630 (2002).
   PubMed Web of Science ®Google Scholar
• Husain S, Alexander BD, Munoz P et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin. Infect. Dis.37, 221–229 (2003).
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis.34, 909–917 (2002).
   PubMed Web of Science ®Google Scholar
• Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect. Dis. Clin. North Am.20, 679–697 (2006).
   PubMed Web of Science ®Google Scholar
• Ernst EJ, Roling EE, Petzold CR et al.In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother.46, 3846–3853 (2002).
   PubMed Web of Science ®Google Scholar
• Bartizal K, Gill CJ, Abruzzo GK et al.In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother.41, 2326–2332 (1997).
   PubMed Web of Science ®Google Scholar
• Louie A, Deziel M, Liu W et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother.49, 5058–5068 (2005).
   PubMed Web of Science ®Google Scholar
• Andes D, Marchillo K, Lowther J et al.In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob. Agents Chemother.47, 1187–1192 (2003).
   PubMed Web of Science ®Google Scholar
• Buell D, Kovand L, Drake T et al. Alternate day dosing of micafungin in treatment of esophageal candidiasis. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 27–30 September 2006 (Abstract M719).
   Google Scholar
• Pappas PG, Rotstein CM, Betts RF et al. Micafungin vs caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis.45, 883–893 (2007).
   PubMed Web of Science ®Google Scholar
• Betts R, Nucci M, Talwar D et al. A multicenter, double-blind trial of a higher caspofungin dose versus standard caspofungin dose in the treatment of invasive candidiasis. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, USA, 25–28 October 2008 (Abstract M1847).
   Google Scholar
• Louie A, Drusano GL, Banerjee P et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents Chemother.42, 1105–1109 (1998).
   PubMed Web of Science ®Google Scholar
• Andes D, Van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob. Agents Chemother.43, 2116–2120 (1999).
   PubMed Web of Science ®Google Scholar
• Andes D, Marchillo K, Stamstad T et al.In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother.47, 3165–3169 (2003).
   PubMed Web of Science ®Google Scholar
• Andes D, Marchillo K, Conklin R et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob. Agents Chemother.48, 137–142 (2004).
   PubMed Web of Science ®Google Scholar
• Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro–in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis.24, 235–247 (1997).
   PubMed Web of Science ®Google Scholar
• Lee SC, Fung CP, Huang JS et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob. Agents Chemother.44, 2715–2718 (2000).
   PubMedGoogle Scholar
• Clancy CJ, Yu VL, Morris AJ et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob. Agents Chemother.49, 3171–3177 (2005).
   PubMed Web of Science ®Google Scholar
• Fan-Havard P, Papano D, Smith SM et al. Development of resistance in candida isolates from patients receiving prolonged antifungal therapy. Antimicrob. Agents Chemother.35, 2302–2305 (1991).
   PubMedGoogle Scholar
• Walmsley S, King S, McGeer A et al. Oropharyngeal candidiasis in patients with human immunodefiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression. Clin. Infect. Dis.32, 1554–1561 (2001).
   PubMedGoogle Scholar
• Vazquez JA, Skiest DJ, Nieto L et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin. Infect. Dis.42, 1179–1186 (2006).
   PubMed Web of Science ®Google Scholar
• Koks CHW, Meenhorst PL, Bult A et al. Itraconazole solution: summary of pharmacokinetic reatures and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected patients. Pharmacol. Res.46, 195–201 (2002).
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Hahn C, Leuner C et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses42, 443–451 (1999).
   PubMed Web of Science ®Google Scholar
• Courtney R, Pai S, Laughlin M et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother.47, 2788–2795 (2003).
   PubMed Web of Science ®Google Scholar
• Ezzet F, Wexler D, Courtney R et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet.44, 211–220 (2005).
   PubMed Web of Science ®Google Scholar
• Courtney R, Wexler D, Radwanski E et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol.57, 218–222 (2004).
   PubMed Web of Science ®Google Scholar
• Gubbins PO, Krishna G, Sansone-Parsons A et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant receipients. Antimicrob. Agents Chemother.50, 1993–1999 (2006).
   PubMed Web of Science ®Google Scholar
• Krishna G, Martinho MS, Chandrasekar P et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy27, 1627–1636 (2007).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis.39, 842–849 (2004).
   PubMedGoogle Scholar
• Purkins L, Wood N, Ghahramani P et al. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob. Agents Chemother.46, 2546–2553 (2002).
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Umemura K, Kondo D et al. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin. Infect. Dis.75, 586–587 (2004).
   Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis.36, 630–637 (2003).
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis.46, 201–211 (2008).
   PubMed Web of Science ®Google Scholar
• Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother.50, 1570–1572 (2006).
   PubMed Web of Science ®Google Scholar
• Segal BH. Aspergillosis. N. Engl. J. Med.360, 1870–1884 (2009).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis.46, 327–360 (2008).
   PubMed Web of Science ®Google Scholar
• Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agens against Candida albicans and Cryptococcus neoformans.Antimicrob. Agents Chemother.44, 1108–1111 (2000).
   PubMed Web of Science ®Google Scholar
• Turnidge JD, Gudmundsson S, Vogelman B et al. The postantibiotic effect of antifungal agents against common pathogenic yeasts. J. Antimicrob. Chemother.34, 83–92 (1994).
   PubMed Web of Science ®Google Scholar
• Andes D, Stamstad T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidasis model. Antimicrob. Agents Chemother.45, 922–926 (2001).
   PubMed Web of Science ®Google Scholar
• Andes D, Safdar N, Marchillo K et al. Pharmacokinetic–pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob. Agents Chemother.50, 674–684 (2006).
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Tam VH, Chi J et al. Pharmacodynamic activity of amphotericin B deoycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother.50, 469–473 (2006).
   PubMed Web of Science ®Google Scholar
• Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect. Dis. Clin. North Am.20, 679–697 (2006).
   PubMed Web of Science ®Google Scholar
• Park BJ, Arthington-Skaggs BA, Hajjeh RA et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob. Agents Chemother.50, 1287–1292 (2006).
   PubMed Web of Science ®Google Scholar
• Bicanic T, Wood R, Meintjes G et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin. Infect. Dis.47, 123–130 (2008).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmbiLoad trial). Clin. Infect. Dis.44, 1289–1297 (2007).
   PubMed Web of Science ®Google Scholar
• Andes D, Van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidasis model. Antimicrob. Agents Chemother.44, 938–942 (2000).
   PubMed Web of Science ®Google Scholar
• Karyotakis NC, Anaissie EJ. Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidasis. Antimicrob. Agents Chemother.40, 2907–2908 (1996).
   PubMedGoogle Scholar
• Hope WW, Warn PS, Sharp A et al. Surface response modeling to examine the combination of amphotericin B deoycholate and 5-fluorocytosine for treatment of invasive candidiasis. J. Infect. Dis.192, 673–680 (2005).
   PubMed Web of Science ®Google Scholar
• Te Dorsthorst DT, Verweij PE, Meis JF et al.In vitro interactions between amphotericin B, itraconazole and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models. Antimicrob. Agents Chemother.48, 2007–2013 (2004)
   PubMed Web of Science ®Google Scholar
• Te Dorsthorst DT, Verweij PE, Meis JF et al. Efficacy and pharmadynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis. Antimicrob. Agents Chemother.49, 4220–4226 (2005).
   PubMedGoogle Scholar
• Karyotakis NC, Anaissie EJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin. Infect. Dis.15, 1003–1018 (1992).
   PubMedGoogle Scholar